Literature DB >> 15575357

Screening of pregnant women for hepatitis B markers in a French Provincial University Hospital (Limoges) during 15 years.

François Denis1, Sylvie Ranger-Rogez, Sophie Alain, Marcelle Mounier, Caroline Debrock, Anne Wagner, Christian Delpeyroux, Jean Louis Tabaste, Yves Aubard, Pierre-Marie Preux.   

Abstract

During the 15 years from January 1984 to December 1998 the Limoges University Hospital screened 22,859 pregnant patients for hepatitis B surface antigen (HBs Ag) and identified 149 positives. The overall prevalence (0.65%) was intermediate between prevalences observed among women of French origin (0.29%), French West Indies islands (5.68%) and of foreign origin particulary South East Asian origin (7.14%) and Sub Saharan African origin (6.52%). Hepatitis B Virus (HBV) replication markers was detected with relative low frequence (HBe Ag: 14.4%; HBV-DNA: 13.7-20%) among HBs Ag positive mothers. Markers of delta hepatitis virus was found among 10.5% of the HBs Ag carrier pregnant women. During the 15 years study period variations of the global prevalence were not statistically significant. Universal prenatal screening and infant immunisation could greatly contribute to the control of HBV infection if the polemic about the hepatitis B vaccination recently propagated in France will not have a negative effect on the acceptance and national programme of vaccination.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15575357     DOI: 10.1007/s10654-004-5755-9

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  28 in total

1.  [Incidence of hepatitis B markers in pregnancy. Comparison with the serological tests legally required for maternal care].

Authors:  P Mariss; E Haubold
Journal:  Dtsch Med Wochenschr       Date:  1986-11-14       Impact factor: 0.628

2.  Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial.

Authors:  R P Beasley; L Y Hwang; C C Lin; C E Stevens; K Y Wang; T S Sun; F J Hsieh; W Szmuness
Journal:  Lancet       Date:  1981-08-22       Impact factor: 79.321

3.  Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal).

Authors:  P Maupas; J P Chiron; F Barin; P Coursaget; A Goudeau; J Perrin; F Denis; I D Mar
Journal:  Lancet       Date:  1981-02-07       Impact factor: 79.321

Review 4.  Hepatitis B maternal-fetal transmission in Southern Europe.

Authors:  G Papaevangelou; G Farmaki; H Kada
Journal:  Intervirology       Date:  1998       Impact factor: 1.763

5.  [Prevalence of HBs Ag in about 21,500 pregnant women. Survey at twelve French University Hospitals. The Muticentric Study Group].

Authors:  F Denis; J L Tabaste; S Ranger-Rogez
Journal:  Pathol Biol (Paris)       Date:  1994-05

6.  [Prevalence of HBs antigen carriers and markers of B virus replication in a population of pregnant women, in France].

Authors:  F Roudot-Thoraval; F Kouadja; V Wirquin; V Thiers; P Avons; C Brechot; D Dhumeaux
Journal:  Gastroenterol Clin Biol       Date:  1989-04

7.  Hospital-based evaluation of programs to prevent perinatal hepatitis B virus transmission.

Authors:  H R Yusuf; F J Mahoney; C N Shapiro; E E Mast; L Polish
Journal:  Arch Pediatr Adolesc Med       Date:  1996-06

8.  Prevention of vertical transmission of hepatitis B. The place of routine screening in antenatal care, and the case for immunization of infants at risk.

Authors:  G L Gilbert
Journal:  Med J Aust       Date:  1984-08-18       Impact factor: 7.738

Review 9.  Review: protective efficacy of hepatitis B vaccines in neonates.

Authors:  F E André; A J Zuckerman
Journal:  J Med Virol       Date:  1994-10       Impact factor: 2.327

10.  Prevention of perinatal transmission of hepatitis B virus (HBV) to children of e antigen-positive HBV carrier mothers by hepatitis B immune globulin and HBV vaccine.

Authors:  K Kanai; A Takehiro; H Noto; M Nishida; K Takahashi; Y Kawashima; Y Igarashi; K Matsushita; M Shimizu
Journal:  J Infect Dis       Date:  1985-02       Impact factor: 5.226

View more
  7 in total

Review 1.  Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus.

Authors:  Ahizechukwu C Eke; George U Eleje; Uzoamaka A Eke; Yun Xia; Jiao Liu
Journal:  Cochrane Database Syst Rev       Date:  2017-02-11

2.  Perinatal hepatitis B prevention program in Shandong Province, China. Evaluation and progress.

Authors:  Li Zhang; Stephen Ko; Jingjing Lv; Feng Ji; Bingyu Yan; Fujie Xu; Aiqiang Xu
Journal:  Hum Vaccin Immunother       Date:  2014-11-06       Impact factor: 3.452

3.  Survey of HBsAg-positive pregnant women and their infants regarding measures to prevent maternal-infantile transmission.

Authors:  Yan Guo; Jianqiong Liu; Liping Meng; Hu Meina; Yukai Du
Journal:  BMC Infect Dis       Date:  2010-02-15       Impact factor: 3.090

4.  [Seroprevalence of HBsAg in pregnant women in central Morocco].

Authors:  Mohammed Sbiti; Hanane Khalki; Imane Benbella; Lhoussaine Louzi
Journal:  Pan Afr Med J       Date:  2016-07-01

5.  Changes in the Prevalence of HBsAg and HBeAg: a Study of 8696 Parturients in a Well Vaccinated Area.

Authors:  Chen-Hsuan Wu; Te-Yao Hsu; Fu-Tsai Kung; Chan-Chao ChangChien; Ching-Chang Tsai; Sheng-Nan Lu
Journal:  Sci Rep       Date:  2017-04-27       Impact factor: 4.379

6.  Hepatitis B virus infection among pregnant women in Taiwan: comparison between women born in Taiwan and other southeast countries.

Authors:  Ching-Chiang Lin; Hsiu-Shu Hsieh; Yu-Jie Huang; Yeou-Lih Huang; Ming-Kun Ku; Hsin-Chia Hung
Journal:  BMC Public Health       Date:  2008-02-07       Impact factor: 3.295

Review 7.  Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.

Authors:  Susan J M Hahné; Irene K Veldhuijzen; Lucas Wiessing; Tek-Ang Lim; Mika Salminen; Marita van de Laar
Journal:  BMC Infect Dis       Date:  2013-04-18       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.